Abstract: Compositions and treatments for inducing tumor regression by activating inflammasomes in tumor cells and tumor-associated cells. A tumor in a subject is treated by administering a composition to the subject that activates inflammasomes in cells of the tumor and thereby causes tumor cell pyroptosis and tumor regression.

Abstract: Provided herein is technology relating to treating and/or ameliorating TNF? cytotoxicity and particularly, but not exclusively, to compositions, methods, and kits for specifically modulating BCL-2-associated death promoter (BAD) activity, for example, by modulating the activity of Src and/or p190GAP.

Abstract: Methods and devices are disclosed for implementing quantum information processing based on electron spins in semiconductor and transition metal compositions. The transition metal electron orbitals split under semiconductor crystal field. The electron ground states are used as qubits. The transitions between the ground states involve electron spin flip. The semiconductor and transition metal compositions may be further included in optical cavities to facilitate quantum information processing. Quantum logic operations may be performed using single color or two color coherent resonant optical excitations via an excited electron state.

Abstract: A computing device may receive a first set of training data for training an ANN to predict output data for a first task, and may train the ANN with the first set of training data by only adjusting values of weights associated with a first subset of neurons, the first subset selected based on an identity of the first task. The computing device may receive a second, different set of training data for training the ANN to predict output data for a second task, and may train the ANN with the second set of training data by only adjusting values of weights associated with a second subset of neurons, the second subset selected based on an identity of the second task. During training, adjusting of the value of any weight may entail weight stabilization that depends on whether there has been any training for one or more previous tasks.

Abstract: One aspect of the present invention describes materials and methods of quantitatively measuring the density or percent occupancy of DNA binding proteins such as histones, histone variants, histone post translational modifications and transcription factors in chromatin at given DNA loci. One embodiment measures a factor's average quantity at specific gene loci, and controls for a number of pitfalls concerning antibody quality and handling issues. Other embodiments include calibrating and quantifying chromatin immunoprecipitation assays, assessing an affinity reagent specificity, as well as required reagents and their formulation in kits. Another embodiment allows for the diagnosis of a condition or disease by measuring the DNA density of a histone modification at a genomic locus.

Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

Abstract: The present invention provides microfluidic technology enabling rapid and economical manipulation of reactions on the femtoliter to microliter scale.

Abstract: Systems and methods of continuous cooling at cryogenic temperatures. One exemplary aspect involves a refrigeration system that includes: a chamber adapted to hold liquid and gaseous coolant received from a cooling pot; a first adsorption pump having an inlet end in fluid communication with the chamber, the first adsorption pump configured to capture gas from the liquid and gaseous coolant when the first adsorption pump is enabled; a second adsorption pump having an inlet end in fluid communication with the chamber, the second adsorption pump configured to capture gas from the liquid and gaseous coolant when the second adsorption pump is enabled; a first heater or heat switch for desorbing the gas captured by the first adsorption pump; and a second heater or heat switch for desorbing the gas captured by the second adsorption pump.

Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.

Abstract: The present invention features linear and three-dimensional supramolecular materials self-assembled from block co-polymers comprising oligo(ethylene sulfide) (OES). The block copolymers assemble into fibrils, micelles, or matrices. The fibrillar materials are sensitive to oxidation, which leads to decreased OES block hydrophobicity and crystallinity, and increased water solubility of the polymer constituents. Molecular loading options, coupled with oxidative sensitivity, allow implantable or injectable fibrillar suspensions or cross-linked three-dimensional matrices to demonstrate significant biomedical potential, especially in the context of extracellular and intracellular molecular delivery and applications related to infection and disease.

Abstract: Described herein are methods for modulation of the activity of the carotid body that afford therapeutic benefit for sleep-related breathing disorders and related conditions.

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating a specified set of genes. Specifically, methods may comprise calculating a prognosis score based on a particular algorithm. Also disclosed are compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more upstream activators and/or downstream effectors of TET1.

Abstract: The present invention provides microfabricated substrates and methods of conducting reactions within these substrates. The reactions occur in plugs transported in the flow of a carrier-fluid.

Abstract: Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.

Abstract: Provided herein are Si-based materials, methods of making the Si-based materials, and methods for using the Si-based materials. In embodiments, a silicon-based material comprises an aggregate of particles, the particles comprising an ordered array of nanostructures, the nanostructures comprising amorphous silicon, wherein at least some pairs of adjacent nanostructures are connected by one or more bridges comprising amorphous silicon, the one or more bridges extending from the surface of one nanostructure of the pair to the surface of the other nanostructure in the pair.

Abstract: The present invention relates to a compound having a structure according to formula (I) or a salt thereof, wherein: R1 is a branched or linear alkyl, acyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, or hydroxy-alkinyl residue comprising 6 to 30 carbon atoms, R2 is selected from the group consisting of: a) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal or cyclic quaternary ammonium, b) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal amino group and/or 1 to 3 hydroxyl groups, c) an amino acid residue, d) a five or six carbon sugar and e) H, R3 is a residue selected from the group consisting of an alkyl, alkenyl, prostanyl-dialkyl, furanyl-dialkyl, cyclobutyl-dialkyl, cycloalkyl and aryl group of 2 to 40 carbon atoms length and comprising at least one keto group, epoxy group, aldehyde group, peroxy group, hydroperoxy group, hydroxyl group or a free carboxyl group, L1 is selected from the group consisting of O, NH, S, CH2, (aa), (bb), (cc), (dd), (ee), (ff), (gg)

Abstract: A device and method integrates a lesion stager in a reporting tool. The method includes receiving a user input. The user input is image data including at least one variable value. The variable value is indicative of a variable parameter of the image data. The method includes associating each of the at least one variable value with a corresponding variable parameter to generate at least one variable-value pair. The method includes determining a computed output value as a function of select ones of the at least one variable-value pair.

Abstract: Metal-organic framework (MOFs) compositions based on nitrogen donor-based organic bridging ligands, including ligands based on 1,3-diketimine (NacNac), bipyridines and salicylaldimine, were synthesized and then post-synthetically metalated with metal precursors, such as complexes of first row transition metals. Metal complexes of the organic bridging ligands could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

Abstract: This disclosure is directed to compositions and methods for utilizing the boundaries of the C-terminal domains of Nucleoprotein from Zaire Ebola virus as highly stable recombinant protein antigens to generate antibodies for diagnosis and treatment of Ebola virus infection.

Abstract: Indoline and tetrahydroquinoline sulfonyl compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (“MBLs”), such as NDM-1 are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the compounds disclosed herein.